Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

2.590 +0.250 (+10.68%)
Streaming Delayed Price Updated: 3:24 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics Inc

< Previous 1 2 3 4 Next >
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024
GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics: Q4 Earnings Insights
Via Benzinga
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023
GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb... 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction 
From Gain Therapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
Gain Therapeutics' GBA1 Parkinson's disease focused GT-02287's mechanism of action, tackling GCase misfolding to enhance lysosomal activity. 
Via Benzinga
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST 
From Gain Therapeutics, Inc.
Via GlobeNewswire
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
From Gain Therapeutics, Inc.
Via GlobeNewswire
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the... 
Via Benzinga
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule 
From Gain Therapeutics, Inc.
Via GlobeNewswire
These Apple Insiders Are Selling Shares of AAPL Stock
Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL. 
Via InvestorPlace
Why Is Nvni Group (NVNI) Stock Down 8% Today?
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.